Changeflow GovPing Pharma & Drug Safety N-Phenyl-Pyrazolo[1,5-A]pyridine Derivatives Tr...
Routine Guidance Added Final

N-Phenyl-Pyrazolo[1,5-A]pyridine Derivatives Treat Urticaria

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)
Published March 11th, 2026
Detected March 26th, 2026
Email

Summary

The European Patent Office has published patent application EP4626884A1 concerning N-Phenyl-Pyrazolo[1,5-A]pyridine derivatives as inhibitors for treating urticaria. The application lists Blueprint Medicines Corporation as the applicant.

What changed

The European Patent Office has published patent application EP4626884A1, detailing N-Phenyl-Pyrazolo[1,5-A]pyridine derivatives developed by Blueprint Medicines Corporation. These compounds are identified as wild type c-Kit kinase inhibitors intended for the treatment of urticaria and other related conditions, as indicated by the IPC classifications.

This publication represents a new patent filing and does not impose immediate compliance obligations on regulated entities. However, it is relevant for pharmaceutical companies and drug manufacturers monitoring intellectual property and therapeutic developments in the field of immunology and dermatology. Compliance officers in the pharmaceutical sector should note this filing for competitive intelligence and potential future licensing or research considerations.

Source document (simplified)

← EPO Patent Bulletin

N-PHENYL-PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS WILD TYPE C-KIT KINASE INHIBITORS FOR THE TREATMENT OF URTICARIA

Publication EP4626884A1 Kind: A1 Mar 11, 2026

Applicants

Blueprint Medicines Corporation

Inventors

BRUBAKER, Jason, D., DAI, Yinghui, DINEEN, Thomas, A., DU, Guangyan, FANG, Cheng, HAIDLE, Andrew, Marc, KIM, Joseph, L., PEROLA, Emanuele, SAMARAKOON, Thiwanka, WILSON, Douglas

IPC Classifications

C07D 471/04 20060101AFI20240607BHEP A61K 31/437 20060101ALI20240607BHEP A61P 3/10 20060101ALI20240607BHEP A61P 9/12 20060101ALI20240607BHEP A61P 11/00 20060101ALI20240607BHEP A61P 11/06 20060101ALI20240607BHEP A61P 17/00 20060101ALI20240607BHEP A61P 17/06 20060101ALI20240607BHEP A61P 25/00 20060101ALI20240607BHEP A61P 25/28 20060101ALI20240607BHEP A61P 29/00 20060101ALI20240607BHEP A61P 35/00 20060101ALI20240607BHEP A61P 35/02 20060101ALI20240607BHEP A61P 37/00 20060101ALI20240607BHEP A61P 37/02 20060101ALI20240607BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Classification

Agency
EPO
Published
March 11th, 2026
Instrument
Guidance
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP4626884A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Development Patent Filing
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Healthcare Drug Development

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.